|
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Clinical research trials and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer. Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer  Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
For Condition: Langerhans cell histiocytosis,childhood non-Hodgkin's lymphoma,childhood Hodgkin's lymphoma,hematopoietic and lymphoid cancer
Status: Recruiting
Sponsor(s): Herbert Irving Comprehensive Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of donor peripheral stem cell transplantation in treating patients who have hematologic cancer.
Details: OBJECTIVES: - Determine the efficacy and safety of allogeneic peripheral blood stem cell transplantation in achieving engraftment in patients with hematologic malignancy. - Determine the hematopoietic recovery, incidence of chemoradiotherapeutic toxicity, relapse, graft-versus-host disease, and survival of patients treated with this regimen. OUTLINE: Patients receive a preparative chemoradiotherapeutic regimen and graft-versus-host disease prophylaxis prior to transplantation. Patients undergo allogeneic peripheral blood stem cell transplantation on day 0. Patients are followed every 1-2 weeks for 6 months and at 9, 12, 24, and 36 months. PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study within 4 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /65 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Diagnosis of one of the following: - Chronic myelogenous leukemia - Philadelphia chromosome-positive OR - Molecular evidence of bcr/abl gene rearrangement - Acute myeloid leukemia, acute lymphocytic leukemia, lymphoma, histiocytoses, myelodysplasia, juvenile chronic myelomonocytic leukemia, aplastic anemia, paroxysmal nocturnal hemoglobinuria, or Fanconi's anemia - Confirmed by cytochemistry, immunophenotyping, and/or chromosomal abnormalities - Multiple myeloma - Hereditary immunodeficiency disorders - Confirmed by immunologic determination - Sickle cell anemia or beta-thalassemia - Confirmed by hemoglobin electrophoresis - Storage disorders (e.g., Gaucher's disease, Hurler's disease, or metachromatic leukodystrophy) - Confirmed by metabolic testing - Other non-malignant conditions - Eligible for allogeneic peripheral blood stem cell or bone marrow transplantation PATIENT CHARACTERISTICS: Age: - 65 and under Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Not specified PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DavidSavage, Study Chair, Columbia University
Herbert Irving Comprehensive Cancer Center at Columbia University *Recruiting*
New York City, New York, 10032
United States
Recruiting David Savage 212-305-9327
Additional Information:
Study ID Numbers: CDR0000068388; CPMC-CAMP-016,CPMC-IRB-7651,NCI-G00-1891
Study Start Date:
Record last reviewed: November 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00008216
Other Langerhans Cell Histiocytosis Studies:
1. Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
2. Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
Related Studies:
Other Langerhans cell histiocytosis Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
|
|
|
|
|
|
|
|
